Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia ... to go off ...

044). Conversely, 6 taxa, such as rhodospirillaceae, defluviitaleaceae, and desulfovibrio, were protective against schizophrenia (OR: 0.88-0.94; P ≤.049). The findings may provide evidence for the ...

Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of ...

About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients. Treatment adherence is a big challenge for patients with schizophrenia ...

An extended version of a digital-face intervention known as avatar therapy is safe and effective for quieting auditory ...

"This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a new alternative to the antipsychotic medications people with ...

Schizophrenia is derived from two Greek ... fixed and sometimes strange beliefs that aren’t based in reality and the person refuses to give them up even when provided evidence against them. A person ...

This is a largely unmet need in schizophrenia treatment, as traditional medications provide little relief in this area. “Cobenfy doesn’t cause the weight gain and motor side effects we often see with ...